Repare Therapeutics

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA. In addition to this presentation, the Company will p.

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY. A live webcast of the fireside chat can be accessed in the Investor section of the Company's we.

Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Cathie Wood's ARK Genomic Revolution ETF is a top shareholder of Repare Therapeutics. Wood, along with several Wall Street analysts, hold an overtly bullish view on the biotech's growth prospects.

Wall Street Thinks This Cathie Wood Stock Could Jump by 187%

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.91 per share a year ago.

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023. “During the second quarter we made great progress advancing our clinical programs and presenting novel findings from our ongoing clinical trials, including reporting on camonsertib's combination with three PARP inhibitors and initial clinical proof of co.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point, California. A live webcast of the fireside chat can be accessed in the Investor s.

Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1 inhibitor in molecularly selected advanced solid tumors. “These initial proof of concept results for lunresertib monotherapy show a favorable and distinct tolerability pro.

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), were published in Nature Medicine. The article, entitled “Camonsertib in DNA.

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein.

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc., (Nasdaq: RPTX), (“Repare”, or “the Company”), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company's EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company's common shares. The award was approved by the Compensation Committee of the Company's Board of Direct.

Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.83 per share a year ago.

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023. “We continue to execute clinically and across our pipeline programs, including presenting initial clinical data of camonsertib in combination with various PARP inhibitors from the ongoing TRESR and ATTACC trials at this year's AACR conference,” said Lloy.

Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2023. Concurrent with Dr. Molineaux's appointment as of the date of the annual meeting, Jerel Davis, Ph.D., Managing Director at Versant Ventures and a fou.

Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), in combination with a poly (ADP-ribose) polymerase inhibitor (PARPi), tala

Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida.

Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

NEW YORK , Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX

Velo3D

Cathie Wood – the billionaire investor who recently called her flagship fund “the new Nasdaq” has been loading up on shares of the following two small-cap stocks in recent days. Velo3D Inc (NYSE: VLD) The first one that's caught her eye is this Velo3D – a California-based provider of metal 3D printing solutions.

Cathie Wood has been building stakes in two little-known stocks

The famed money manager scooped up shares of a metal 3D printing firm and a clinical-stage oncology treatment company.

Cathie Wood's Ark Invest has loaded up on these 2 small-cap names for the last 7 trading sessions

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rptx. The investigation concerns whether Repare has violated federal securities laws.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation

After losing some value lately, a hammer chart pattern has been formed for Repare Therapeutics Inc. (RPTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Repare Therapeutics Inc. (RPTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CAMBRIDGE, Mass. & MONTREAL--( BUSINESS WIRE )--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”). The payment reflects achievement of a specified research trigger, under the companies' 2019 Strategic Partnership Agreement (“Ono Agreement”). Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan. “This reflects an important milestone in our RP-2119 Polθ program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023,” said Kim A. Seth, Chief Business Officer of Repare.

Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

News for Repare Therapeutics Stock (RPTX)